v3.25.3
Intangible Assets and Goodwill - Narrative (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Jul. 02, 2024
Sep. 30, 2023
Goodwill [Line Items]              
Amortization and impairment of acquired intangible assets $ 135,700,000 $ 130,300,000 $ 378,400,000 $ 295,500,000      
Amortization of intangible assets 135,700,000 110,100,000 374,900,000 275,300,000      
Impairment of intangible assets 0 $ 20,200,000 3,500,000 $ 20,200,000      
Accumulated impairment losses related to goodwill $ 0   $ 0        
Minimum              
Goodwill [Line Items]              
Estimated life (in years) 2 years   2 years        
Maximum              
Goodwill [Line Items]              
Estimated life (in years) 31 years   31 years        
Acquired and in-licensed rights and patents              
Goodwill [Line Items]              
Weighted-Average remaining useful life 12 years   12 years        
Reata Pharmaceuticals, Inc | Priority review voucher              
Goodwill [Line Items]              
Intangible assets:             $ 100,000,000
Human Immunology Biosciences              
Goodwill [Line Items]              
Intangible assets:           $ 1,600,000,000  
Human Immunology Biosciences | In-process research and development              
Goodwill [Line Items]              
Intangible assets: $ 1,600,000,000   $ 1,600,000,000   $ 1,600,000,000